Immune checkpoint inhibitor-associated Colitis / Intestinal inflammation (ICIAC)

Immune checkpoint inhibitors (ICIs) can induce immune-related adverse events such as immune-mediated enterocolitis (IMC)
Groenewegen et al. 2023 Journal of Immunotherapy 46(6): 216-220

Intestinal inflammation is caused by excessive activation of IFN-gamma-producing CD4+ T cells.
There is also a depletion of peripherally induced regulatory T cells via Fcγ receptor signaling.
Lo et al. 2024 Science 383: 62-70

Enterocolitis is among the leading adverse events associated with immune checkpoint inhibitors (ICIs).
Grover et al. 2020 JOP 16: e933–e942

Increased representation of bacteria belonging to the Bacteroidetes phylum is correlated with resistance to the development of Checkpoint-Blockade-Induced Colitis
Dubin et al. 2016

see also:
Adverse Events / Safety & Immune Checkpoint Inhibitors (ICIs)
Immune Checkpoint Inhibitors (ICIs) Therapy & Drugs/Treatments to improve
Immune Checkpoint Inhibitors (ICIs) & Inflammatory Bowel Disease (IBD)